By Dr Louise Emmett

Journal articles

Meijer D; van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; van de Ven PM; van der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN, 2021, 'External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study', European Urology, 80, pp. 234 - 242, http://dx.doi.org/10.1016/j.eururo.2021.05.006

Turner RM; Dieng M; Khanna N; Nguyen M; Zeng J; Nijhuis AAG; Nieweg OE; Einstein AJ; Emmett L; Lord SJ; Menzies AM; Thompson JF; Saw RPM; Morton RL, 2021, 'Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA–D Melanoma', Annals of Surgical Oncology, 28, pp. 4561 - 4569, http://dx.doi.org/10.1245/s10434-020-09270-3

Mei R; Bracarda S; Emmett L; Farolfi A; Lambertini A; Fanti S; Castellucci P, 2021, 'Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [⁶⁸Ga]-Ga-PSMA-11 PET/CT', Clinical and Translational Imaging, 9, pp. 215 - 220, http://dx.doi.org/10.1007/s40336-021-00421-4

Luiting HB; Remmers S; Meijer D; Vis AN; Donswijk M; Oprea-Lager DE; Emmett L; Rauscher I; Van der Poel HG; Roobol MJ; van Leeuwen PJ, 2021, 'External Validation of Two Nomograms Developed for ⁶⁸Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer ¹⁸F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?', European Urology Open Science, 28, pp. 47 - 51, http://dx.doi.org/10.1016/j.euros.2021.04.002

Bagguley D; Ong S; Buteau JP; Koschel S; Dhiantravan N; Hofman MS; Emmett L; Murphy DG; Lawrentschuk N, 2021, 'Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer', Future Oncology, 17, pp. 2225 - 2241, http://dx.doi.org/10.2217/fon-2020-1293

Long GV; Atkinson V; Lo S; Guminski AD; Sandhu SK; Brown MP; Gonzalez M; Scolyer RA; Emmett L; McArthur GA; Menzies AM, 2021, 'Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).', Journal of Clinical Oncology, 39, pp. 9508 - 9508, http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9508

Ceci F; Oprea-Lager DE; Emmett L; Adam JA; Bomanji J; Czernin J; Eiber M; Haberkorn U; Hofman MS; Hope TA; Kumar R; Rowe SP; Schwarzenboeck SM; Fanti S; Herrmann K, 2021, 'E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 1626 - 1638, http://dx.doi.org/10.1007/s00259-021-05245-y

Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID; Dhiantravan N; Ford K; Langford A; Lawrence N; McDonald W; Rana N; Subramaniam S; Yip S, 2021, '[¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial', The Lancet, 397, pp. 797 - 804, http://dx.doi.org/10.1016/S0140-6736(21)00237-3

Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J, 2021, '⁶⁸Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 477 - 482, http://dx.doi.org/10.1007/s00259-020-04944-2

Roberts MJ; Morton A; Donato P; Kyle S; Pattison DA; Thomas P; Coughlin G; Esler R; Dunglison N; Gardiner RA; Doi SA; Emmett L; Yaxley J, 2021, 'Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2)', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 655 - 656, http://dx.doi.org/10.1007/s00259-020-04983-9

Fendler WP; Calais J; Eiber M; Simko JP; Kurhanewicz J; Santos RD; Feng FY; Reiter RE; Rettig MB; Nickols NG; Kishan AU; Shozo O; Emmett L; Zacho HD; Ilhan H; Rischpler C; Wetter A; Schoder H; Burger IA; Slavik R; Carroll PR; Lawhn-Heath C; Herrmann K; Czernin J; Hope TA, 2021, 'False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial', European Journal of Nuclear Medicine and Molecular Imaging, 48, pp. 501 - 508, http://dx.doi.org/10.1007/s00259-020-04945-1

Ende J; Amin A; Sheehan-Dare G; Cusick T; Ho B; Keane J; Nguyen A; Liu V; Lee J; Chan L; Chen A; Fullard K; Stricker P; Emmett L, 2021, 'Pilot Trial Comparing the Performance of 68Ga-PSMA-11 PET/CT to 18F-PSMA-1007 PET/ CT in the Detection of Prostate Cancer Recurrence in Men with Rising PSA Following Radical Prostatectomy', Journal of Radiology and Medical Imaging, https://meddocsonline.org/journal-of-radiology-and-medical-imaging/pilot-trial-comparing-the-performance-of-68Ga-PSMA-11-PET-CT-to-18F-PSMA-1007-PET-CT-in-the-detection-of-prostate-cancer-recurrence-in-men-with-rising-PSA-following-radical-prostatectomy.pdf

McGeorge S; Kwok M; Jiang A; Emmett L; Pattison DA; Thomas PA; Yaxley JW; Roberts MJ, 2021, 'Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review', Advances in Urology, 2021, http://dx.doi.org/10.1155/2021/1544208

Lawhn-Heath C; Salavati A; Behr SC; Rowe SP; Calais J; Fendler WP; Eiber M; Emmett L; Hofman MS; Hope TA, 2021, 'Prostate-specific membrane antigen PET in prostate cancer', Radiology, 299, pp. 248 - 260, http://dx.doi.org/10.1148/RADIOL.2021202771

Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G, 2021, 'Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of ¹⁸F-DCFPyL PET/CT Restaging', Advances in Radiation Oncology, 6, http://dx.doi.org/10.1016/j.adro.2020.08.010

Meijer D; Van Leeuwen PJ; Roberts MJ; Siriwardana AR; Morton A; Yaxley JW; Samaratunga H; Emmett L; Van De Ven PM; Van Der Poel HG; Donswijk ML; Boellaard TN; Schoots IG; Oprea-Lager DE; Coughlin GD; Vis AN, 2021, 'External validation and addition of PSMA-PET to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: An international multicenter study', European Urology Open Science, 33, pp. S191 - S193, http://dx.doi.org/10.1016/s2666-1683(21)03073-1

De Bono J; Delaney E; Emmett L; Florisson D; Ghani M; Kemp S; Smith J, 2021, 'M13 Cardiac Surgery Advanced Life Support – A Unique Approach and Learning Program', Heart, Lung and Circulation, 30, pp. S6 - S7, http://dx.doi.org/10.1016/j.hlc.2021.03.022

Zamboglou C; Schmidt-Hegemann NS; Emmett L; Strouthos I; Ferentinos K; Serani F; Farolfi A; Fanti S; Federica M; Lanzafame H; Kirste S; Ruf J; Vrachimis A; Ceci F; Grosu AL; Henkenberens C, 2021, 'Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis', European Urology Open Science, 33, pp. S261 - S262, http://dx.doi.org/10.1016/s2666-1683(21)03122-0

Meijer D; van Leeuwen P; Roberts M; Siriwardana A; Morton A; Yaxley J; Samaratunga H; Emmett L; van de Ven P; van der Poel H; Donswijk M; Boellaard T; Schoots I; Oprea-Lager D; Coughlin G; Vis A, 2021, 'MP11-13 EXTERNAL VALIDATION AND ADDITION OF PSMA-PET TO THE MOST FREQUENTLY USED NOMOGRAMS FOR THE PREDICTION OF PELVIC LYMPH-NODE METASTASES: AN INTERNATIONAL MULTICENTER STUDY', Journal of Urology, 206, http://dx.doi.org/10.1097/ju.0000000000001984.13

Gondoputro W; Blazevski A; Amin A; Scheltema M; Agrawal S; Cusick T; Van Leeuwen P; Van Leeuwen F; Emmett L; Thompson J; Stricker P, 2021, 'MP50-05 INTERIM RESULTS FROM THE DETECT TRIAL: A PROSPECTIVE CLINICAL TRIAL EVALUATING ^99M TC-LABELLED PSMA RADIOGUIDED SURGERY TO AID THE INTRAOPERATIVE DETECTION OF LYMPH NODE METASTASES DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION FOR PROSTATE CANCER', Journal of Urology, 206, http://dx.doi.org/10.1097/ju.0000000000002076.05

Hagens MJ; Oprea-Lager DE; Vis AN; Wondergem M; Donswijk ML; Meijer D; Emmett L; Van Leeuwen PJ; Van Der Poel HG, 2021, 'Reproducibility of tumor staging depends on the applied PSMA-radiotracer - A retrospective analysis on the interobserver variability of PSMA-PET/CT', European Urology Open Science, 33, pp. S194 - S197, http://dx.doi.org/10.1016/s2666-1683(21)03074-3

Emmett L; Hruby G, 2020, 'Clinical impact of PET imaging in prostate cancer management', Current Opinion in Urology, 30, pp. 649 - 653, http://dx.doi.org/10.1097/MOU.0000000000000795

Emmett L, 2020, 'Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer', Seminars in Oncology Nursing, 36, http://dx.doi.org/10.1016/j.soncn.2020.151052

Lee J; Emmett L; Tang R; Ho B; Earls P; Matthews T; Gallagher R, 2020, 'Prospective evaluation of the impact of human papilloma virus status and small node size on the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for primary head and neck squamous cell carcinoma', ANZ Journal of Surgery, 90, pp. 1396 - 1401, http://dx.doi.org/10.1111/ans.16093

Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P, 2020, '3-year freedom from progression after ⁶⁸Ga-PSMA PET/CT-Triaged management in men with biochemical recurrence after radical prostatectomy: Results of a prospective multicenter trial', Journal of Nuclear Medicine, 61, pp. 866 - 872, http://dx.doi.org/10.2967/jnumed.119.235028

Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ, 2020, 'Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (⁶⁸Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection', BJU International, 125, pp. 876 - 883, http://dx.doi.org/10.1111/bju.15052

Hofman MS; Emmett L; Sandhu SK; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams S; Martin AJ; Davis ID, 2020, 'TheraP: A randomised phase II trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).', Journal of Clinical Oncology, 38, pp. 5500 - 5500, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5500

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L, 2020, 'Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer', BJU International, 125, pp. 515 - 524, http://dx.doi.org/10.1111/bju.14999

Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G, 2020, 'A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy', International Journal of Radiation Oncology Biology Physics, 106, pp. 546 - 555, http://dx.doi.org/10.1016/j.ijrobp.2019.11.001

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ, 2020, 'Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature', BJU International, 125, pp. 206 - 214, http://dx.doi.org/10.1111/bju.14944

Emmett L; Hofman MS, 2020, 'Editorial Comment', Journal of Urology, 203, pp. 99, http://dx.doi.org/10.1097/01.JU.0000605568.03568.2c

Holtkamp LHJ; Chakera AH; Fung S; Stretch JR; Saw RPM; Lee K; Ch'Ng S; Gonzalez M; Thompson JF; Emmett L; Nieweg OE, 2020, 'Staging ¹⁸F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases', Melanoma Research, pp. 358 - 363, http://dx.doi.org/10.1097/CMR.0000000000000666

Scheltema MJ; Chang JI; Stricker PD; van Leeuwen PJ; Nguyen QA; Ho B; Delprado W; Lee J; Thompson JE; Cusick T; Spriensma AS; Siriwardana AR; Yuen C; Kooner R; Hruby G; O'Neill G; Emmett L, 2019, 'Diagnostic accuracy of ⁶⁸Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of ⁶⁸Ga-PSMA PET to mpMRI', BJU International, 124, pp. 42 - 49, http://dx.doi.org/10.1111/bju.14794

Lieng H; Kneebone A; Hayden AJ; Christie DRH; Davis BJ; Eade TN; Emmett L; Holt T; Hruby G; Pryor D; Sidhom M; Skala M; Yaxley J; Shakespeare TP, 2019, 'Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group', Radiotherapy and Oncology, 140, pp. 68 - 75, http://dx.doi.org/10.1016/j.radonc.2019.05.016

Hofman MS; Emmett L; Violet J; Y. Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; Davis ID, 2019, 'TheraP: a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)', BJU International, 124, pp. 5 - 13, http://dx.doi.org/10.1111/bju.14876

Hofman MS; Emmett L, 2019, 'Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength?', European Urology, 76, pp. 479 - 481, http://dx.doi.org/10.1016/j.eururo.2019.07.030

van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L, 2019, 'Gallium-68-prostate-specific membrane antigen (⁶⁸Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer', BJU International, 124, pp. 62 - 68, http://dx.doi.org/10.1111/bju.14506

Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM, 2019, 'Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAF^V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial', The Lancet Oncology, 20, pp. 961 - 971, http://dx.doi.org/10.1016/S1470-2045(19)30331-6

Fendler WP; Calais J; Eiber M; Flavell RR; Mishoe A; Feng FY; Nguyen HG; Reiter RE; Rettig MB; Okamoto S; Emmett L; Zacho HD; Ilhan H; Wetter A; Rischpler C; Schoder H; Burger IA; Gartmann J; Smith R; Small EJ; Slavik R; Carroll PR; Herrmann K; Czernin J; Hope TA, 2019, 'Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial', JAMA Oncology, 5, pp. 856 - 863, http://dx.doi.org/10.1001/jamaoncol.2019.0096

Yin C; Ho B; Chan L; Emmett L, 2019, 'Asymptomatic Prostate Cancer Brain Metastases on 68Ga-PSMA PET/CT', Clinical Nuclear Medicine, 44, pp. E382 - E384, http://dx.doi.org/10.1097/RLU.0000000000002548

Emmett L; Metser U; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Punwani S; Pond G; Chua S; Ho B; Johnston E; Pouliot F; Scott AM, 2019, 'Prospective, multisite, international comparison of ¹⁸F-fluoromethylcholine PET/CT, multiparametric MRI, and ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in men with high-risk features and biochemical failure after radical prostatectomy: Clinical performance and patient outcomes', Journal of Nuclear Medicine, 60, pp. 794 - 800, http://dx.doi.org/10.2967/jnumed.118.220103

Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM, 2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

Nandurkar R; Van Leeuwen P; Stricker P; Woo H; Kooner R; Yuen C; O'Neill G; Ende D; Cusick T; Ho B; Hickey A; Emmett L, 2019, '68Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery', British Journal of Radiology, 92, http://dx.doi.org/10.1259/bjr.20180667

van Leeuwen PJ; Emmett L; Donswijk ML; Stricker PD; Pos FJ; Wit E; van der Poel HG, 2019, 'Early outcomes after [⁶⁸Ga]PSMA-PET/CT guided salvage therapy in men with biochemical recurrence after radical prostatectomy', Tijdschrift voor Urologie, 9, pp. 2 - 8, http://dx.doi.org/10.1007/s13629-018-00215-w

Crumbaker M; Emmett L; Horvath LG; Joshua AM, 2019, 'Exceptional response to ¹⁷⁷lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM, 2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial ⁶⁸Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Pond G; Scott AM; Tunariu N; Sidhu H; Emmett L, 2019, 'The contribution of multiparametric pelvic and whole-body MRI to interpretation of ¹⁸F-fluoromethylcholine or ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure after radical prostatectomy', Journal of Nuclear Medicine, 60, pp. 1253 - 1258, http://dx.doi.org/10.2967/jnumed.118.225185

Liu W; Fakir H; Randhawa G; Kassam Z; Chung HT; Chung P; Ward A; Zukotynski K; Emmett L; Bauman G, 2019, '2 Drive: Defining Radiorecurrent Intraprostatic Target Volumes', Radiotherapy and Oncology, 139, pp. S4 - S4, http://dx.doi.org/10.1016/s0167-8140(19)33259-1

Back to profile page